Meet the Startup Trying to Out-Ozempic Ozempic

Ambrosia Biosciences closes an oversubscribed $100M Series B to launch US trials for a novel oral GLP-1 drug

6 Apr 2026

The obesity drug race just got another serious contender. On March 31, 2026, Boulder-based Ambrosia Biosciences closed a $100 million Series B to fund US clinical trials for a small-molecule GLP-1 pill designed to outperform what's already on the market.

The oversubscribed round was co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital, with BVF Partners, Boulder Ventures, Janus Henderson Investors, and Samsara BioCapital also participating. Proceeds go directly toward launching Phase 1 trials for Ambrosia's lead drug, a non-peptide GLP-1 receptor agonist built from the ground up to beat first-generation oral competitors.

That distinction matters. Where today's dominant treatments rely on peptide-based formulations, Ambrosia's molecule is engineered for full 24-hour receptor coverage at low doses. It's also designed to combine cleanly with drugs targeting related metabolic pathways, including GIP and amylin, a feature that looks smarter by the day as obesity treatment moves toward multi-drug regimens.

The timing is deliberate. Just one day after Ambrosia's raise closed, the FDA approved Eli Lilly's oral obesity pill Foundayo, effectively confirming that the pill-based metabolic market is no longer theoretical. Analysts project oral GLP-1 therapies will capture roughly 20 percent of a global obesity drug market that could reach $80 billion by decade's end.

Ambrosia's founding team comes with serious credentials. Alumni of Array BioPharma, they collectively count more than 30 investigational new drug applications, 25 new molecular entities, and seven FDA approvals among their careers. Merck's involvement in the company's $25 million Series A in 2024 offered early institutional validation. Blue Owl's Sara Clarke, a co-lead on this round, described Ambrosia as well-positioned to deliver best-in-class therapies as oral GLP-1s reshape the treatment landscape.

The company enters clinical development at a moment of genuine market inflection. Competition will be fierce, but Ambrosia arrives with the funding, the pedigree, and a scientific rationale built for where obesity medicine is heading next.